Cancer :: Alternative Phase II Trial Design Could Reduce Phase III Failures
An alternative design for phase II cancer clinical trials may improve success rates for new cancer drugs in phase III trials.
An alternative design for phase II cancer clinical trials may improve success rates for new cancer drugs in phase III trials.
The difficulty in penetrating tumors and reaching all of the cancer cells is an important but under-appreciated cause of drug resistance in solid tumors, according to a review article.
In a commentary, Richard Hill, Ph.D., of the University of Toronto and Roberto Perris, Ph.D., of the University of Parma in Italy discuss the need for a more accurate definition of cancer stem cells.
Consuming large amounts of caffeine while taking acetaminophen, one of the most widely used painkillers in the United States, could potentially cause liver damage, according to a preliminary laboratory study reported in the Oct. 15 print issue of ACS’ Chemical Research in Toxicology, a monthly journal.
The University of Rochester Medical Center received $1.5 million to develop a blood test for concussions by isolating proteins that can predict memory loss, chronic headaches or other neurological problems.
Hallmarks of autism are characteristic behaviors — repetitive motions, problems interacting with others, impaired communication abilities — that occur in widely different combinations and degrees of severity among those who have the condition.
Preliminary research suggests that in children at increased risk for type 1 diabetes, dietary intake of omega-3 fatty acids was associated with a reduced risk of pancreatic islet autoimmunity, which is linked to the development of diabetes, according to an article in the Sept. 26 issue of JAMA.
Patients in Hong Kong who were newly diagnosed with coronary artery disease had nearly twice the prevalence of colorectal tumors and cancers, with this association stronger in persons who had smoked or have the metabolic syndrome, according to a study in the Sept. 26 issue of JAMA.
Over a decade in the making, the WalkAide® System is a small device that makes a big difference for its users. Now the Canadian invention is receiving international recognition as a recipient of a 2007 da Vinci Award, to be presented by General Motors at the Ritz-Carlton Hotel, Dearborn, MI, on Friday, September 28, 2007.
Birds, fish and amphibians can do something that humans and other mammals generally cannot: re-grow damaged or lost inner ear hair cells. Loss of these cells causes hearing deficiencies and disabling balance problems in an estimated 250 million people worldwide.